Qiagen to consolidate and expand in Maryland; Myriad Genetics leads Utah Dx labs in Medicare-related revenue;

> Qiagen ($QGEN), the Dutch diagnostics and lab testing giant, said it would combine three Maryland sites into two campuses in the state and invest $10 million more to accommodate future growth. Story

> Exact Sciences ($EXAS), developer of the Cologuard colon cancer test, ended up raising nearly $138 million in a secondary offering of 11.5 million shares, a larger-than-expected haul in which underwriters exercised their 1.5-million-share overallotment option. Story (reg. req.)

> Utah's Myriad Genetics ($MYGN) pulls in twice as much revenue from Medicare as all other diagnostics laboratories and related businesses in the state combined, according to an analysis of federal data. Story

> At a recent conference, California's ICB International unveiled a new tracer that helped image alpha-synuclein in the brains of Parkinson's-like mice. Release

> Saladax Biomedical is rolling out a blood test to help doctors better manage the use of a particular chemotherapy drug for various cancers. Release

> Invetech will back the development and production of Biocartis' platform for biomarker analysis, both companies announced on April 15. Story (reg. req.)

> A new blood-based biomarker could help predict breast cancer recurrence and a patient's treatment response. Story

Suggested Articles

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.

Janssen tapped Resolution Bioscience to develop a companion diagnostic for Zejula in patients with metastatic castration-resistant prostate cancer.